Opinions, beliefs and knowledge of people with multiple sclerosis on COVID-19 pandemic and vaccine

Mult Scler Relat Disord. 2021 Sep:54:103113. doi: 10.1016/j.msard.2021.103113. Epub 2021 Jun 26.

Abstract

Background: Considering the potential COVID-19 impact on pwMS health and the importance of vaccination for this population, we decided to assess: (a) pwMS' beliefs and knowledge on COVID-19 pandemic; (b) their acceptance towards COVID-19 vaccination and (c) pwMS' opinions on general vaccination.

Methods: Observational study, based on a cross-sectional (10-20th September 2020) online survey, conducted in a cohort of pwMS' followed at two Portuguese hospitals. The survey included measures to characterize the sample and a questionnaire designed to assess the topics defined for this study.

Results: 270 respondents completed the full survey (response rate 58.2%). pwMS greatest concern during the pandemic was an aggravation of MS, especially by patients older than 50 years old. Almost 40% of the patients older than 50 felt that the pandemic negatively affected their MS related medical assistance. Most patients believed they would recover from COVID-19 infection. More than half of the responders feared a MS aggravation if they got COVID-19; this was more pronounced in patients with progressive MS. About 12% of the participants did not want to be vaccinated and almost 40% was unsure. Regarding vaccines in general, almost a third of the participants feared their side effects or MS related complications.

Conclusion: Having knowledge of pwMS' opinions on COVID-19 pandemic impact and vaccination is useful to better address these issues. Fears and expectations towards vaccination must be discussed with pwMS.

Keywords: COVID-19 pandemic; multiple sclerosis; opinions; questionnaire; vaccines.

Publication types

  • Observational Study

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Cross-Sectional Studies
  • Humans
  • Middle Aged
  • Multiple Sclerosis* / epidemiology
  • Pandemics / prevention & control
  • SARS-CoV-2
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines